


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method for treating a cardiovascular disorder, comprising administering to a patient a therapeutically effective amount of a compound ~~Compound~~ of the formula



in which

E represents methylene, NH, an oxygen atom or a sulphur atom,

m represents 0, 1, 2 or 3,


n represents 1, 2 or 3,

R¹ represents halogen, hydroxyl, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, hydroxycarbonyl, aminocarbonyl, alkoxycarbonyl, alkylaminocarbonyl or -NH(C=O)OR⁹,

where

R⁹ represents (C₁-C₆)-alkyl, (C₃-C₇)-cycloalkyl, (C₆-C₁₀)-aryl, (C₃-C₇)-cycloalkylmethyl or (C₆-C₁₀)-arylmethyl,

R² represents a group of the formula



where

* represents the point of attachment to the pyrazoline ring,

X represents R³ or (C₁-C₈)-alkylene-R⁴,

where alkylene may be substituted by 1 to 4 fluorine atoms,

Y represents R³ or (C₁-C₈)-alkylene-R⁴,

where alkylene may be substituted by 1 to 4 fluorine atoms,

R³ represents 1,3-benzodioxole, 2,2-difluoro-1,3-benzodioxole, 2,3-dihydro-1,4-benzodioxin, 2,2,4,4-tetrafluoro-4H-1,3-benzodioxin, indanyl, 1,2,3,4-tetrahydronaphthyl, (C₆-C₁₀)-aryl, 5- to 10-membered heteroaryl, (C₃-C₆)-cycloalkyl or 5- to 10-membered heterocyclyl,

where aryl, heteroaryl, cycloalkyl or heterocyclyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of hydroxyl, amino, halogen, cyano, nitro, monohalomethyl, dihalomethyl, trihalomethyl, monohalomethoxy, dihalomethoxy, trihalomethoxy, alkyl, alkoxy,

alkylamino, aryl, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylcarbonylamino and alkylsulphonyl,

R⁴ represents hydrogen, 1,3-benzodioxole, 2,2-difluoro-1,3-benzodioxole, 2,3-dihydro-1,4-benzodioxin, 2,2,4,4-tetrafluoro-4H-1,3-benzodioxin, indanyl, 1,2,3,4-tetrahydronaphthyl, (C₆-C₁₀)-aryl, 5- to 10-membered heteroaryl, (C₃-C₇)-cycloalkyl, 5- to 10-membered heterocyclyl, hydroxyl, cyano, trifluoromethyl, optionally fluorine-substituted alkylthio, -OR⁵, -C(=O)R⁶ or -NR⁷R⁸,

where aryl, heteroaryl, cycloalkyl or heterocyclyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of hydroxyl, amino, halogen, cyano, nitro, oxo, monohalomethyl, dihalomethyl, trihalomethyl, monohalomethoxy, dihalomethoxy, trihalomethoxy, alkyl, optionally alkoxycarbonyl-substituted alkoxy, alkylamino, aryl, benzyl, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylcarbonylamino and alkylsulphonyl,

R⁵ represents optionally fluorine-substituted alkyl, (C₆-C₁₀)-aryl, benzyl, (C₃-C₇)-cycloalkyl or alkylcarbonyl,

where aryl, benzyl or cycloalkyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of hydroxyl, amino, halogen, cyano, nitro, oxo, monohalomethyl, dihalomethyl, trihalomethyl, monohalomethoxy, dihalomethoxy, trihalomethoxy, alkyl, alkoxy, alkylamino, aryl, benzyl, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, alkyl-

aminocarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylcarbonyl-amino and alkylsulphonyl,

R⁶ represents hydroxyl, amino, alkyl, alkylamino, alkoxy, (C₆-C₁₀)-aryl, benzyloxy or 5- to 10-membered heterocyclyl,

where aryl or benzyloxy may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of hydroxyl, amino, halogen, cyano, nitro, oxo, monohalomethyl, dihalomethyl, trihalomethyl, monohalomethoxy, dihalomethoxy, trihalomethoxy, alkyl, alkoxy, alkylamino, aryl, benzyl, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, alkylamino-carbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylcarbonylamino and alkylsulphonyl,


R⁷ represents hydrogen, alkyl or benzyl,

R⁸ represents hydrogen, alkyl, phenyl, alkylcarbonyl, alkoxycarbonyl, alkylsulphonyl, optionally alkyl-substituted arylcarbonyl or optionally alkyl-substituted arylsulphonyl,

or a pharmaceutically acceptable salt thereof ~~and its salts, its solvates and the solvates of its salts~~

~~for the treatment and/or prophylaxis of diseases .~~

2. (currently amended) A method for treating a cardiovascular disorder, comprising administering to a patient a therapeutically effective amount of a compound ~~Compound~~ of the formula



in which

E represents methylene, NH, an oxygen atom or a sulphur atom,

m represents 0, 1, 2 or 3,


n represents 1, 2 or 3,

R¹ represents halogen, hydroxyl, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, hydroxycarbonyl, aminocarbonyl, alkoxycarbonyl, alkylaminocarbonyl or -NH(C=O)OR⁹,

where

R⁹ represents (C₁-C₆)-alkyl, (C₃-C₇)-cycloalkyl, (C₆-C₁₀)-aryl, (C₃-C₇)-cycloalkylmethyl or (C₆-C₁₀)-arylmethyl,

R² represents a group of the formula



where

* represents the point of attachment to the pyrazoline ring,

X represents R^3 or (C_1-C_8) -alkylene- R^4 ,

where alkylene may be substituted by 1 to 4 fluorine atoms,

Y represents (C_1-C_8) -alkylene- R^4 ,

where alkylene may be substituted by 1 to 4 fluorine atoms,

R^3 represents 1,3-benzodioxole, 2,2-difluoro-1,3-benzodioxole, 2,3-dihydro-1,4-benzodioxin, 2,2,4,4-tetrafluoro-4H-1,3-benzodioxin, indanyl, 1,2,3,4-tetrahydronaphthyl, (C_6-C_{10}) -aryl, 5- to 10-membered heteroaryl, (C_3-C_6) -cycloalkyl or 5- to 10-membered heterocyclyl,

where aryl, heteroaryl, cycloalkyl or heterocyclyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of hydroxyl, amino, halogen, cyano, nitro, monohalomethyl, dihalomethyl, trihalomethyl, monohalomethoxy, dihalomethoxy, trihalomethoxy, alkyl, alkoxy, alkylamino, aryl, hydroxycarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylcarbonylamino and alkylsulphonyl,

R^4 represents hydrogen, 1,3-benzodioxole, 2,2-difluoro-1,3-benzodioxole, 2,3-dihydro-1,4-benzodioxin, 2,2,4,4-tetrafluoro-4H-1,3-benzodioxin, indanyl, 1,2,3,4-tetrahydronaphthyl, (C_6-C_{10}) -aryl, 5- to 10-membered heteroaryl, (C_3-C_7) -cycloalkyl, 5- to 10-membered heterocyclyl, hydroxyl, cyano, trifluoromethyl, optionally fluorine-substituted alkylthio, $-OR^5$, $-C(=O)R^6$ or $-NR^7R^8$,

where aryl, heteroaryl, cycloalkyl or heterocyclyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of hydroxyl, amino, halogen, cyano, nitro, oxo, monohalomethyl, dihalomethyl, trihalomethyl, monohalomethoxy, dihalomethoxy, trihalomethoxy, alkyl, optionally alkoxy-carbonyl-substituted alkoxy, alkylamino, aryl, benzyl, hydroxycarbonyl, alkoxy-carbonyl, aminocarbonyl, alkyl-aminocarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylcarbonyl-amino and alkylsulphonyl,

R⁵ represents optionally fluorine-substituted alkyl, (C₆-C₁₀)-aryl, benzyl, (C₃-C₇)-cycloalkyl or alkylcarbonyl,

where aryl, benzyl or cycloalkyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of hydroxyl, amino, halogen, cyano, nitro, oxo, monohalomethyl, dihalomethyl, trihalomethyl, monohalomethoxy, dihalomethoxy, trihalomethoxy, alkyl, alkoxy, alkylamino, aryl, benzyl, hydroxycarbonyl, alkoxy-carbonyl, aminocarbonyl, alkyl-aminocarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylcarbonyl-amino and alkylsulphonyl,

R⁶ represents hydroxyl, amino, alkyl, alkylamino, alkoxy, (C₆-C₁₀)-aryl, benzyloxy or 5- to 10-membered heterocyclyl,

where aryl or benzyloxy may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of hydroxyl, amino, halogen, cyano, nitro, oxo, monohalomethyl, dihalomethyl, trihalomethyl, monohalomethoxy, dihalomethoxy, trihalomethoxy, alkyl, alkoxy, alkylamino, aryl, benzyl, hydroxycarbonyl, alkoxy-carbonyl, aminocarbonyl, alkylamino-

carbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylcarbonylamino and alkylsulphonyl,

R^7 represents hydrogen, alkyl or benzyl,

R^8 represents hydrogen, alkyl, phenyl, alkylcarbonyl, alkoxy carbonyl, alkylsulphonyl, optionally alkyl-substituted arylcarbonyl or optionally alkyl-substituted arylsulphonyl,

or a pharmaceutically acceptable salt thereof ~~and its salts, its solvates and the solvates of its salts .~~

3. (currently amended) The method of ~~Compound according to~~ Claim 2 , wherein
~~in which~~


E represents methylene, NH or an oxygen atom,

m represents 0, 1 or 2,

n represents 1, 2 or 3,

R^1 represents halogen, amino, cyano, nitro, trifluoromethyl, alkyl or alkoxy,

R^2 represents a group of the formula



where

* denotes the point of attachment to the pyrazoline ring,

X represents R^3 or (C_1-C_8) -alkylene- R^4 ,

Y represents (C_1-C_8) -alkylene- R^4 ,

R^3 represents 1,3-benzodioxole, 2,2-difluoro-1,3-benzodioxole, 2,3-dihydro-1,4-benzodioxin, 2,2,4,4-tetrafluoro-4H-1,3-benzodioxin, indanyl, 1,2,3,4-tetrahydronaphthyl, phenyl, 5- or 6-membered heteroaryl, (C_3-C_6) -cycloalkyl or 5- or 6-membered heterocyclyl,

where phenyl, heteroaryl, cycloalkyl or heterocyclyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of hydroxyl, amino, halogen, cyano, nitro, trichloromethyl, trifluoromethyl, monofluoromethoxy, difluoromethoxy, trifluoromethoxy, (C_1-C_4) -alkyl, (C_1-C_4) -alkoxy, (C_1-C_4) -alkylamino, phenyl, hydroxycarbonyl, (C_1-C_4) -alkoxy-carbonyl, aminocarbonyl, (C_1-C_4) -alkylaminocarbonyl and (C_1-C_4) -alkylcarbonyl,

R^4 represents hydrogen, 1,3-benzodioxole, 2,2-difluoro-1,3-benzodioxole, 2,3-dihydro-1,4-benzodioxin, 2,2,4,4-tetrafluoro-4H-1,3-benzodioxin, indanyl, 1,2,3,4-tetrahydronaphthyl, phenyl, naphthyl, 5- or 6-membered heteroaryl, (C_5-C_6) -cycloalkyl, 5- or 6-membered heterocyclyl, cyano, trifluoromethyl, $-OR^5$, $-C(=O)R^6$ or $-NR^7R^8$,

where phenyl, naphthyl, heteroaryl, cycloalkyl or heterocyclyl may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of hydroxyl, amino, halogen, cyano, nitro, oxo, trichloromethyl, trifluoromethyl, monofluoromethoxy, difluoromethoxy, trifluoromethoxy, (C_1-C_4) -alkyl,

(C₁-C₄)-alkoxy, (C₁-C₄)-alkylamino, phenyl, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl, aminocarbonyl, (C₁-C₄)-alkylamino-carbonyl and (C₁-C₄)-alkylcarbonyl,

R⁵ represents optionally fluorine-substituted (C₁-C₄)-alkyl, phenyl, benzyl or (C₁-C₄)-alkylcarbonyl,

R⁶ represents (C₁-C₄)-alkoxy,

R⁷ represents hydrogen or (C₁-C₄)-alkyl,

R⁸ represents (C₁-C₄)-alkyl or optionally (C₁-C₄)-alkyl-substituted phenylcarbonyl,

or a pharmaceutically acceptable salt thereof ~~and its salts, its solvates and the solvates of its salts .~~

4. (currently amended) The method of ~~Compound according to~~ Claim 2 ~~or 3~~ ,

in which


E represents methylene, NH or an oxygen atom,

m represents 0, 1 or 2,

n represents 1, 2 or 3,

R¹ represents halogen, amino, cyano, trifluoromethyl, (C₁-C₄)-alkyl or (C₁-C₄)-alkoxy,

R² represents a group of the formula



where

* represents the point of attachment to the pyrazoline ring,

X represents R^3 or (C_1-C_6) -alkylene- R^4 ,

R^3 represents 1,3-benzodioxole, 2,2-difluoro-1,3-benzodioxole, 2,3-dihydro-1,4-benzodioxin, 2,2,4,4-tetrafluoro-4H-1,3-benzodioxin, phenyl, 5- or 6-membered heteroaryl or (C_3-C_6) -cycloalkyl,

where phenyl, heteroaryl or cycloalkyl may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of halogen, cyano, trichloromethyl, trifluoromethyl, monofluoromethoxy, difluoromethoxy, trifluoromethoxy, (C_1-C_4) -alkyl and (C_1-C_4) -alkoxy,

R^4 represents hydrogen, phenyl, 5- or 6-membered heteroaryl, (C_5-C_6) -cycloalkyl, 5- or 6-membered heterocyclyl, cyano, trifluoromethyl, $-OR^5$ or $-NR^7R^8$,

where phenyl, heteroaryl, cycloalkyl or heterocyclyl may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of halogen, cyano, oxo, trichloromethyl, trifluoromethyl, monofluoromethoxy, difluoromethoxy, trifluoromethoxy, (C_1-C_4) -alkyl and (C_1-C_4) -alkoxy,

R^5 represents optionally fluorine-substituted (C_1-C_4) -alkyl,

R^7 represents hydrogen or (C_1-C_4) -alkyl,

R^8 represents (C_1-C_4) -alkyl,

or a pharmaceutically acceptable salt thereof ~~and its salts, its solvates and the solvates of its salts~~ .

5. (currently amended) The method of claim 2 ~~Compound according to any of Claims 2 to 4~~ ,

in which


E represents methylene,

m represents 1,

n represents 1,

R¹ represents halogen,

R² represents a group of the formula



where

* represents the point of attachment to the pyrazoline ring,

X represents R³ or (C₁-C₆)-alkylene-R⁴,

R³ represents phenyl, 5- or 6-membered heteroaryl or (C₅-C₆)-cycloalkyl,

where phenyl, heteroaryl or cycloalkyl may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of halogen, cyano, trichloromethyl, monofluoromethoxy, difluoromethoxy, trifluoromethyl, trifluoromethoxy, (C₁-C₄)-alkyl and (C₁-C₄)-alkoxy,


R^4 represents hydrogen, phenyl, 5- or 6-membered heteroaryl, (C₅-C₆)-cycloalkyl, 5- or 6-membered heterocyclyl, cyano, trifluoromethyl or -OR⁵,

where phenyl, heteroaryl, cycloalkyl or heterocyclyl may be substituted by 1 or 2 substituents independently of one another selected from the group consisting of halogen, cyano, trichloromethyl, monofluoromethoxy, difluoromethoxy, trifluoromethyl, trifluoromethoxy, (C₁-C₄)-alkyl and (C₁-C₄)-alkoxy,

R^5 represents methyl or ethyl,

or a pharmaceutically acceptable salt thereof ~~and its salts, its solvates and the solvates of its salts .~~

6. (currently amended) A process ~~Process~~ for preparing compounds of the formula (I) as defined in Claim 2, characterized in that a ~~compounds~~ a compound of the formula




in which

R^1 , E, m and n are as defined in Claim 2,

~~are~~ is reacted either

[A] with ~~compounds~~ a compound of the formula



in which

X is as defined in Claim 2 and

Z¹ represents halogen, ~~preferably chlorine or bromine, or hydroxyl,~~

or

[B] with ~~compounds~~ a compound of the formula



in which

Y is as defined in Claim 2,

or

[C] with ~~compounds~~ a compound of the formula




in which

Y is as defined in Claim 2,

or

[D] with ~~compounds~~ a compound of the formula




in which

X is as defined in Claim 2,

or

[E] in two steps first with diphenylcyanocarboimide and then with ~~compounds~~ a compound of the formula



in which

X is as defined in Claim 2.

7. (cancelled)
8. (cancelled)
9. (currently amended) The method of claim 1, wherein the cardiovascular disorder is a
~~Use of a compound of the formula (I) as defined in any of Claims 1 to 5 for preparing a~~
~~medicament for the treatment and/or prophylaxis of thromboembolic disorder disorders.~~
10. (cancelled)
11. (cancelled)
12. (currently amended) A pharmaceutical composition ~~Medicament~~, comprising a
compound of the formula (I) as defined in claim 1 ~~any of Claims 1 to 5~~ in
combination with an inert non-toxic pharmaceutically acceptable auxiliary.
13. (new) The pharmaceutical composition of claim 12, further comprising a further active
compound which is not a compound of formula (1) as defined in claim 1.